drugset / Trial / NCT02596256
Apatinib Plus Docetaxel Versus Docetaxel as Second-line Treatment in Advanced Gastric Cancer (AHEAD-301)
RandomizedParallel-groupOpen-labelTreatment
Summary
Apatinib plus docetaxel versus docetaxel as second-line treatment in advanced gastric cancer.
Timeline
- Start
- 2016-04
- Primary completion
- 2019-02
- Completion
- 2019-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Docetaxel | Small molecule | 60 mg/m2 | Intravenous |
| Subject | Rivoceranib | Small molecule | 500 mg | Oral |